Business Analyst in Pharmaceutical Consulting / May, 2025 — September, 2025

Partnered with top global pharmaceutical companies to deliver market insights opportunity assessments competitive intelligence analysis and support strategic recommendations in novel therapeutic areas across oncology immunology and rare diseases. Conducted primary and secondary research with researchers clinicians patientsconsumers and KOLs to capture disease landscape market trends competitive positioning and strategic implications to develop tailored plans. Monitored and synthesized clinical trial activity to assess product positioning patient segmentation endpoints and regulatory milestones (e.g. FDAEMA designations approvals and guidance updates) into strategic assessments. Managed multiple projects simultaneously and collaborated with cross-functional teams to synthesize clinical and scientific data into business insights and developed client-ready presentations that supported decision-making in RD regulatory and commercial strategy.

Postdoctoral Project Leader, Graduate Research Scientist / January, 2015 — April, 2025

Led research projects in kidney rare diseases and immunology. Formulated hypotheses designed methodologies and protocols and executed experiments to study key biological questions. Conducted qualitative and quantitative research synthesized experimental data critically identified knowledge gaps in the literature and presented research findings. Led a multifunctional collaboration project and integrated the expertise of multiple lab groups (including 3 principal investigators in biomathematics biophysics and molecular biology). Published a number of peer-reviewed scientific articles in high-impact journals including one corresponding first author paper (Tang et al. Cell Reports (2023) Impact Factor 6.9 vs. the average of less than 1). Presented scientific findings at multiple international and local conferences. Experienced in proposal and research grant writing and led members in projects that successfully secured over 1 million Canadian Institutes of Health Research (CIHR) and 100000 Fonds de recherche du Qubec (FRQS) government fundings.